The European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to supply COVID-19 vaccines that was terminated by the UK government this week.

Accordingly, the contract with Valneva also allows for the vaccine to be adapted to new variants of the coronavirus. However, the company has already had a considerable setback: The U.K. cancelled ...

Valneva SE is a vaccine company focused on ... distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable ...

Orders have also been placed for shots made by French company Valneva and Johnson & Johnson subsidiary Janssen. NVX‑CoV2373 is based on the spike protein seen on the surface of the coronavirus ...

While the Novavax and the Sanofi GSK vaccines will not be part of the module, it will look at the circumstances surrounding the Covid-19 jab developed by Valneva. The UK had been due to receive ...

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three ...

Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older The European Commission (EC) will now review ...